Evotec, Inserm, Lille University Hospital and Inserm Transfert enter collaboration

Identification of novel therapeutic targets in obesity and metabolic diseases

31-May-2024 - Evotec SE announced that the Company entered a partnership with Inserm, the French National Institute of Health and Medical Research, Lille University Hospital and Inserm Transfert (the private subsidiary of Inserm) to identify novel therapeutic targets and diagnostic and prognostic markers in ...

Evotec and Owkin enter an A.I.-powered strategic partnership to accelerate therapeutics pipeline in oncology and I&I

04-Jan-2024 - Evotec SE and Owkin, a French-American techbio startup announced an A.I.-powered integrated multi-target collaboration in oncology, immunology and inflammation (“I&I”). The collaboration brings together highly complementary platforms and expertise to accurately select targets, discover and ...

Evotec and Dewpoint Therapeutics enter strategic partnership in oncology

Agreement is based on a risk-sharing arrangement followed by milestone and royalty payments to Evotec based on success of overall programmes

08-Nov-2023 - Evotec SE and Dewpoint Therapeutics announced a strategic R&D collaboration to advance Dewpoint’s leading oncology pipeline programmes of condensate modifying therapeutics (“c-mods”) to Investigational New Drug Applications (“INDs”) using Evotec’s industry-leading fully integrated data-driven ...

New incubator to promote drug discovery and create new therapeutics companies in Singapore

Evotec, ClavystBio, Leaps by Bayer, Lightstone Ventures and Polaris Partners launch "65LAB"

06-Oct-2023 - Evotec SE announced that the Company has entered into a new BRIDGE partnership with Lightstone Ventures, ClavystBio, Leaps by Bayer, Polaris Partners, and the Polaris Innovation Fund. “65LAB”, Evotec’s first academic BRIDGE in Asia, aims to advance drug discovery and the creation of new ...

Evotec provides update on financial impact of cyber-attack

Productivity was affected throughout the entire second quarter

31-Jul-2023 - Evotec SE announced that it is adjusting its guidance for the fiscal year 2023 due to the impact of the cyber-attack. For the current fiscal year, the company now expects Group revenues in the range of € 750 – 790 m (previously € 820 – 840 m); unpartnered R&D is expected in a range of € 60 – 70 ...

Evotec receives US$ 6.6 m grant for drug discovery in tuberculosis

24-Mar-2023 - Evotec SE announced that the Company has received a US$ 6.6 m grant from The Bill & Melinda Gates Foundation for drug discovery in tuberculosis (“TB”). The grant is the second award from the foundation to Evotec supporting TB drug discovery, and allows the Company to progress a portfolio of TB ...

Evotec announces agreement with Janssen to develop immune-based therapies

Strategic partnership in oncology

26-Jan-2023 - Evotec SE announced that the Company has entered into a strategic collaboration and licence agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The collaboration focuses on the development of first-in-class targeted immune-based therapies for ...

Evotec completes acquisition of Central Glass Germany

As Evotec Drug Substance (Germany) GmbH, the acquisition strengthens Evotec's clinical and commercial drug substance manufacturing capacity

04-Nov-2022 - Evotec SE announced that the acquisition of Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co. Ltd., signed in August 2022, has been completed. As Evotec Drug Substance (Germany) GmbH (“Evotec DS”), the strategic transaction strengthens Evotec’s ...

Evotec expands clinical and commercial drug substance manufacturing with acquisition of Central Glass Germany

26-Aug-2022 - Evotec SE announced that the Company expands its clinical and commercial manufacturing platform for small molecule therapeutics by acquiring Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co. Ltd. Going forward, Central Glass Germany GmbH will operate as ...

Three partners committed to combat AMR

Evotec, Boehringer Ingelheim, and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance

07-Jul-2022 - Evotec SE, Boehringer Ingelheim and bioMérieux announced that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR). The resulting company, Aurobac Therapeutics SAS, will combine the best-of-best ...